molnupiravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5377 None

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • molnupiravir
  • EIDD-2801
  • N4-Hydroxycytidine
  • Beta-D-N4-hydroxycytidine
  • NHC
  • MK-4482
EIDD-1931 has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir
  • Molecular weight: 329.31
  • Formula: C13H19N3O7
  • CLOGP: -1.13
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 4
  • TPSA: 140.92
  • ALOGS: -1.81
  • ROTB: 6

Drug dosage:

DoseUnitRoute
1.60 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 2021 PMDA MSD K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 738.52 60.44 188 2008 41217 63445609
Product use issue 530.98 60.44 218 1978 220302 63266524
Accidental underdose 370.85 60.44 56 2140 747 63486079
Product use complaint 360.53 60.44 64 2132 2410 63484416
COVID-19 280.58 60.44 115 2081 112988 63373838
Wrong technique in product usage process 257.34 60.44 92 2104 62248 63424578
Underdose 178.07 60.44 57 2139 27399 63459427
Product use in unapproved indication 169.63 60.44 94 2102 178986 63307840
Accidental overdose 117.33 60.44 40 2156 23269 63463557
COVID-19 pneumonia 62.23 60.44 22 2174 14187 63472639

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 780.25 51.68 194 1866 22733 34932138
Product use issue 601.88 51.68 198 1862 63018 34891853
COVID-19 327.43 51.68 134 1926 77416 34877455
Accidental underdose 269.58 51.68 43 2017 471 34954400
Product use complaint 206.92 51.68 40 2020 1392 34953479
Product use in unapproved indication 192.57 51.68 106 1954 117393 34837478
Wrong technique in product usage process 167.50 51.68 67 1993 35919 34918952
Underdose 136.96 51.68 45 2015 13735 34941136
COVID-19 pneumonia 97.93 51.68 37 2023 16930 34937941
Adverse event 66.86 51.68 29 2031 18848 34936023
Accidental overdose 55.59 51.68 26 2034 20114 34934757

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 1564.86 49.25 368 3969 36824 79703227
Product use issue 1085.12 49.25 409 3928 209413 79530638
Accidental underdose 598.97 49.25 91 4246 771 79739280
Product use complaint 568.66 49.25 101 4236 2382 79737669
COVID-19 564.36 49.25 237 4100 157437 79582614
Wrong technique in product usage process 451.31 49.25 164 4173 73711 79666340
Product use in unapproved indication 341.52 49.25 195 4142 250164 79489887
Underdose 304.50 49.25 100 4237 33051 79707000
Accidental overdose 165.99 49.25 67 4270 39514 79700537
COVID-19 pneumonia 142.53 49.25 55 4282 28794 79711257
Inappropriate schedule of product administration 94.01 49.25 69 4268 133559 79606492
Pneumonia aspiration 82.24 49.25 49 4288 66918 79673133
Drug eruption 61.46 49.25 35 4302 43900 79696151
Adverse event 61.04 49.25 39 4298 60175 79679876
Rash 58.62 49.25 109 4228 578249 79161802
Diarrhoea 51.60 49.25 133 4204 880356 78859695

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB18 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:149553 anticoronaviral drug
CHEBI has role CHEBI:22587 antiviral agents
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:76967 human xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
COVID-19 indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.55 acidic
pKa2 11.55 acidic
pKa3 13.03 acidic
pKa4 4.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
YA84KI1VEW UNII
3258-02-4 SECONDARY_CAS_RN
C5435024 UMLSCUI
CHEBI:180653 CHEBI
CHEBI:51369 CHEBI
CHEMBL4650320 ChEMBL_ID
145996610 PUBCHEM_CID
DB15661 DRUGBANK_ID
11853 INN_ID
C010737 MESH_SUPPLEMENTAL_RECORD_UI
10737 IUPHAR_LIGAND_ID
DB15660 DRUGBANK_ID
018901 NDDF
1201931008 SNOMEDCT_US
1201933006 SNOMEDCT_US
4041077 VANDF
C0067182 UMLSCUI
D11943 KEGG_DRUG
2492423-29-5 SECONDARY_CAS_RN
2587901 RXNORM
354402 MMSL
40179 MMSL
d09837 MMSL
C000656703 MESH_SUPPLEMENTAL_RECORD_UI
197020 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
molnupiravir HUMAN PRESCRIPTION DRUG LABEL 1 0006-5055 CAPSULE 200 mg ORAL Emergency Use Authorization 31 sections
molnupiravir HUMAN PRESCRIPTION DRUG LABEL 1 0006-5055 CAPSULE 200 mg ORAL Emergency Use Authorization 31 sections
molnupiravir HUMAN PRESCRIPTION DRUG LABEL 1 0006-5055 CAPSULE 200 mg ORAL Emergency Use Authorization 31 sections
molnupiravir HUMAN PRESCRIPTION DRUG LABEL 1 0006-5055 CAPSULE 200 mg ORAL Emergency Use Authorization 31 sections